MigraineNCT05175521
Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine
A study testing Eucalyptus Oil Scent and Isopropyl Alcohol Vapors in people with Migraine, run by HonorHealth Research Institute at 1 site in United States.
Trial summary
The goal of this study is to compare the efficacy and adverse events of inhaled isopropyl alcohol vapor (IAV) versus placebo (inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) for treating nausea associated with acute migraine attacks. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Migraine
- What is being tested?
- Eucalyptus Oil Scent and Isopropyl Alcohol Vapors
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 21 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Nov 2021to 1 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients 18 to 65 years old with nausea associated migraines at least twice per month
Who cannot join
- Patients <18 or >65 years old
- Patients without a diagnosis of acute migraine
Trial locations and contacts
1 site in 1 country.
United States1 site
HonorHealth Bob Bové Neuroscience Institute
Scottsdale, Arizona, 85251
About this study
Official title: Double Blind Randomized Control Trial of Inhaled Isopropyl Alcohol Vapors Versus Inhaled Eucalyptus Scent for the Treatment of Nausea Associated With Acute Migraine
The goal of this study is to compare the efficacy and adverse events of inhaled isopropyl alcohol vapor (IAV) versus placebo (inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) for treating nausea associated with acute migraine attacks.
Read the detailed description
The main goal of this study is to examine the efficacy of (nausea reduction and time to use of other anti-nausea medications) and side effects of inhaled isopropyl alcohol vapor (IAV) for treating nausea among migraine patients using a double blind randomized control methodology. IAV is being compared inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) which has not shown benefit for treating nausea or migraine and is therefore considered placebo in this study.
- Conditions
- Migraine
- Being tested
- Eucalyptus Oil Scent, Isopropyl Alcohol Vapors
- Keywords
- Nausea, Isopropyl alcohol, Eucalyptus, Aromatherapy, Vapors
- Medical subject headings
- Migraine Disorders, Nausea
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Eucalyptus Oil ScentOther
Eucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
Isopropyl Alcohol VaporsOther
Isopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack
| Study group | Role | What they receive |
|---|---|---|
| Eucalyptus Oil Scent | Placebo comparator | Eucalyptus oil diluted in mineral oil 1:20 Receives: Other: Eucalyptus Oil Scent |
| Isopropyl Alcohol Vapors | Active comparator | Isopropyl Alcohol 70% Receives: Other: Isopropyl Alcohol Vapors |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change of Severity of Nausea on Nausea Scale
Change in Nausea, modified visual analog score from 0-10 with 10 severe nausea with vomiting, 5 moderate nausea, 1 mild nausea and 0 no nausea.
Measured: ½ hour or to the end of treatment
Secondary outcomes (3)
Side effects associated with interventional substance
Patient written report
Measured: ½ hour, but likely less than 2 hours
Use of anti-nausea medication/Time to use of anti-nausea medication
Did using IAV vs eucalyptus oil change the time until use of oral anti-emetic?
Measured: ½ hour or to the end of treatment
Time to Clinically Relevant Nausea Change
Did IAV vs eucalyptus oil reduce the amount of time the patient experienced nausea with their migraine?
Measured: ½ hour or to the end of treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jan 2022
- Study start11 Nov 2021
- Primary completion31 Dec 2025
- Study completion1 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MigraineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- HonorHealth Research Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jill Rau, MD, PhD, Principal investigator, HonorHealth Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05175521
- Sponsor's protocol ID
- 1718502
- Status last verified
- Apr 2026
- First submitted
- 19 Aug 2021
- Last updated
- 17 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Double Blind Randomized Control Trial of Inhaled Isopropyl Alcohol Vapors Versus Inhaled Eucalyptus Scent for the Treatment of Nausea Associated With Acute Migraine
- ClinicalTrials.gov ID
- NCT05175521
- Acronym / sponsor ID
- 1718502
- Conditions
- Migraine
- Keywords
- Nausea, Isopropyl alcohol, Eucalyptus, Aromatherapy, Vapors
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- HonorHealth Research InstituteUniversity, hospital or other
- Study start
- 11 Nov 2021 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 1 Apr 2026 (actual)
- First posted
- 3 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to compare the efficacy and adverse events of inhaled isopropyl alcohol vapor (IAV) versus placebo (inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) for treating nausea associated with acute migraine attacks.
Detailed description
The main goal of this study is to examine the efficacy of (nausea reduction and time to use of other anti-nausea medications) and side effects of inhaled isopropyl alcohol vapor (IAV) for treating nausea among migraine patients using a double blind randomized control methodology. IAV is being compared inhaled eucalyptus scent (IES) (1:20 dilution in mineral oil) which has not shown benefit for treating nausea or migraine and is therefore considered placebo in this study.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Eucalyptus Oil Scent | Placebo comparator | Other: Eucalyptus Oil ScentEucalyptus oil diluted in mineral oil 1:20 |
| Isopropyl Alcohol Vapors | Active comparator | Other: Isopropyl Alcohol VaporsIsopropyl Alcohol 70% |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients 18 to 65 years old with nausea associated migraines at least twice per month
Key exclusion criteria (2 listed)
- Patients <18 or >65 years old
- Patients without a diagnosis of acute migraine
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Eucalyptus Oil ScentEucalyptus oil in mineral (1:20) will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack | Other | Eucalyptus Oil Scent |
| Isopropyl Alcohol VaporsIsopropyl Alcohol 70% will be inhaled at least 30 minutes after onset of nausea associated with a migraine attack | Other | Isopropyl Alcohol Vapors |
Primary outcome
Change of Severity of Nausea on Nausea Scale
Time frame: ½ hour or to the end of treatment
Change in Nausea, modified visual analog score from 0-10 with 10 severe nausea with vomiting, 5 moderate nausea, 1 mild nausea and 0 no nausea.
3 secondary outcomes
Side effects associated with interventional substance
Time frame: ½ hour, but likely less than 2 hours
Use of anti-nausea medication/Time to use of anti-nausea medication
Time frame: ½ hour or to the end of treatment
Time to Clinically Relevant Nausea Change
Time frame: ½ hour or to the end of treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Apr 2026.
Related trials for Migraine
RecruitingObservational study
Study of the Glymphatic System in Migraine
Migraine
Active, not recruiting
Clinical and Neurophysiological Effects of tDCS to Visual and Motor Cortex in Migraine
Migraine
Active, not recruiting
App-Based Migraine Treatment: The Health enSuite Study
Migraine, Migraine With Aura
Enrolling by invitation
App-based Breathing Program for Migraine Relief
Migraine, Heart Rate Variability (HRV)
Recruiting
Marine Lipids Ease Painful TMD
Temporomandibular Disorder (TMD)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jill Rau, MD, PhD principal investigator
HonorHealth Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Eucalyptus Oil Scent and Isopropyl Alcohol Vapors in people with Migraine, run by HonorHealth Research Institute at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change of Severity of Nausea on Nausea Scale (time frame: ½ hour or to the end of treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2026; AzTrials last refreshed its copy on 8 Nov 2026.